Global Connected Drug Delivery Devices Patent Landscape Report 2024

Global Connected Drug Delivery Devices Market Size

The global connected drug delivery devices market was valued at USD 475.12 million in 2023. It is expected to grow at a CAGR of 23.7% during the forecast period of 2024-2032 and attain a market value of USD 3,222.04 million by 2032.

The market growth is driven by the increasing prevalence of chronic diseases across the globe. Patents are focused on advanced technologies such as near-field communication (NFC) and Bluetooth among connected drug delivery devices and impacting the landscape significantly.

Patent Landscape Report Coverage

The Global Connected Drug Delivery Devices Patent Landscape Report provides a comprehensive and in-depth analysis of the patents in this growing industry. The key sections captured in the report for connected drug delivery devices include a thorough examination of the patent portfolios of key players, covering aspects such as the number of patents and types of technologies patented. It includes the latest trends, geographical distribution of patents, top IP player profiles, technological segmentation, and patent valuation associated with Connected Drug Delivery Devices. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within Connected Drug Delivery Devices technologies.

Key Inclusions

• Patent Valuation Analysis

An evaluation and competitive benchmarking of key members of unique patent families are covered in the analysis for connected drug delivery device technologies. The important parameters have been taken into consideration including IP document, year of application, number of citations, time to expiry, and jurisdiction associated with connected drug delivery devices.

• Analysis of Patent Applications

A comprehensive summary of several patent applications which were filed across different jurisdictions for connected drug delivery devices, and their relative value are covered. The analysis will cover the capital in terms of innovation and innovation type.

• Analysis of Granted Patents

Detailed analysis of the granted patents across different jurisdictions for connected drug delivery devices and their relative value in the IP are covered in the final report.

Connected Drug Delivery Devices Patent Outlook

• IoT and smart technology integration are improving the effectiveness of medication delivery and personalization, encouraging healthcare providers to adopt it.

• Through real-time monitoring and reminders, connected drug delivery devices enhance patient compliance and result in better treatment outcomes.

• The development and adoption of connected drug delivery technologies are facilitated by favourable regulatory frameworks and reimbursement models, which in turn supports market growth and influences the patent landscape positively.

What are Connected Drug Delivery Devices?

Connected drug delivery devices are cutting-edge medical devices that monitor, track, and manage medicine administration by integrating digital connectivity features like sensors and wireless communication. They improve treatment optimization, adherence, and overall patient outcomes by giving patients and healthcare professionals access to real-time data.

The components of connected drug delivery devices include connected sensors, connected inhaler sensors, injection sensors, inhalation devices, injection devices and others. Streamlining patient care and increasing efficiency, these devices integrate several tasks, including data transmission, medication delivery, and monitoring into a single system. It allows healthcare providers and patients to share data easily, which enables prompt and more individualized interventions.

Connected Drug Delivery Devices Industry Growth Drivers

Technological Advancement is Expected to Boost the Patent Industry Growth

The creation of complex and effective linked drug delivery devices is made possible by the ongoing innovation in healthcare technology. For instance, for better management of asthma and COPD, Novartis introduced the Sandoz Symbicort Inhaler, a connected inhaler that incorporates cutting-edge sensor technology to track patient usage and send data to healthcare professionals.

With the advent of improved and innovative technologies, there is an increase in patent activity which focuses on enhancing the performance of connected drug delivery devices. There were 6,937 patents granted in 2022 and by 2023 around 7,448 patents were granted. Patents covering these technologies are crucial for companies, thus impacting the connected drug delivery device patent landscape.

Rising Demand for Personalized Medicine is Expected to Propel Connected Drug Delivery Devices Patent Industry
 
The adoption of connected drug delivery devices, which enable customized medication regimens based on individual patient data is being fueled by an increasing emphasis on personalized treatment approaches.

Connected Drug Delivery Devices Patent Segmentation

The report will cover the following sections in detail:

Analysis by Product Type

• Standalone Components & Software

• Integrated Devices
  • Inhalation Devices
  • Injection Devices

• Others

Analysis by Technology

• Bluetooth Drug Delivery Devices

• Near Field Communication Drug Delivery Devices

Connected Drug Delivery Devices Patent Segmentation Analysis

The breakup based on product type includes standalone components and software, integrated devices and others. Integrated devices are further categorised into inhalation and injection devices. Detailed technological data will be provided for all specified segments classified in this report.

Connected Drug Delivery Devices Patent Jurisdiction Analysis

The United States is one of the leading jurisdictions for connected drug delivery devices patents, having around 235,000+ patents. The presence of big companies, well-established healthcare infrastructure, and advanced research and development activities contributes to the regional patent landscape significantly.

Patent Profile of Key Companies

Among the players with connected drug delivery devices patent families, new entrants have been identified, which can be either established companies or startups developing their first technology in the connected drug delivery devices field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:

Medtronic Inc

Medtronic Inc. is a leading medical technology company with its headquarters located in Dublin, Ireland. It was founded in 1949. Through creative and data-driven solutions, the company is actively engaged in the development of connected drug delivery devices aimed at improving patient outcomes.

Sanofi SA

A well-known international pharmaceutical company, Sanofi S.A. was established in 1973 and has its headquarters in Paris, France. Using cutting-edge digital technologies, the company focuses on creating connected drug delivery devices that enhance patient adherence and treatment outcomes.

Other companies include Becton, Dickinson and Company, Genentech Inc, Boston Scientific Scimed Inc, Massachusetts Inst Technology, Cardiac Pacemakers Inc, Novo Nordisk As, Dexcom Inc, Amgen Inc, Regeneron Pharma, Abbott, F. Hoffmann La Roche, Alnylam Pharmaceuticals Inc, and Ethicon Endo Surgery Inc, among others.

Reasons to Purchase this Report

The Connected Drug Delivery Devices Patent Report provides information on the intellectual property (IP) position and strategy of key players. This report can help companies and players looking to enter or invest in this field by -

• Competitive Advantage: The landscape reveals the market leaders, potential partners and innovators and makes it understandable which companies have important patents in this field of connected drug delivery devices.

• Innovation Insights: The patent analysis reveals new innovations and technologies in connected drug delivery devices.

• Market Positioning: Companies with strong patent portfolios gain a competitive advantage because their intellectual property assets differentiate their products. Understanding their intellectual property strategy reveals the market position of new entrants and potential barriers to entry within the connected drug delivery devices patent landscape.

• Risk Assessment: In technology-intensive fields such as connected drug delivery devices, risks of IP infringement are common. Analyzing patent landscapes helps companies assess risk, develop mitigation strategies, and inform licensing, partnering, and acquisition decisions.

Key Questions Answered in the Connected Drug Delivery Devices Patent Landscape Report

• Who are the key players in the connected drug delivery devices patent landscape?
• How is the patent portfolio distributed geographically?
• What are the emerging trends in connected drug delivery device patents?
• How has the patent landscape evolved over time?
• What are the strategic insights for market players and investors?
• What is the technological focus of patents in the connected drug delivery devices industry?
• How do patent strategies impact competitive advantage?
• What are the implications of patent filings in connected drug delivery devices?
• What are the challenges and opportunities in the connected drug delivery devices patent landscape?
• What are the regulatory and legal considerations?
• What technological innovations have recently emerged in connected drug delivery devices?

Related Reports

Night Vision Devices Market

Ophthalmic Viscoelastic Devices (OVD) Market

Laparoscopy Devices Market